Ascenta Therapeutics, Inc.
http://www.ascenta.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ascenta Therapeutics, Inc.
Akari, Peak Bio Hatch Merger Plan To Survive Together
Deal snapshot: Akari, which has stayed afloat through small financings in recent years, and Peak Bio, after going public via the SPAC route in 2022, will merge as equals and then prioritize their pipeline.
Amgen Doubles Down On AI, Genomic Investments In R&D
David Reese, chief technology officer and former EVP of R&D, and newly appointed EVP of R&D Jay Bradner spoke with Scrip about how Amgen is pairing artificial intelligence with genomics plus data milestones in 2024.
Amgen, J&J, Takeda R&D Heads On The Era Of Human Data, Treating Disease Earlier
Big pharma R&D leaders discuss the confluence of technology and biotech driving insights into biology and how industry is doing in terms of identifying patients earlier in disease.
Hyloris Raises €15m In Private Equity Offering
Value-added medicines firm Hyloris has raised €15m from new and existing investors through a private equity offering of nearly one million new shares.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice